van Warmerdam LJ - Search Results

1

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

van Warmerdam LJ, Rodenhuis S, van der Wall E, Maes RA, Beijnen JH. van Warmerdam LJ, et al. Among authors: van der wall e. Br J Cancer. 1996 Apr;73(8):979-84. doi: 10.1038/bjc.1996.191. Br J Cancer. 1996. PMID: 8611435 Free PMC article.

2

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RA, Beijnen JH. van Warmerdam LJ, et al. J Clin Oncol. 1995 Jul;13(7):1768-76. doi: 10.1200/JCO.1995.13.7.1768. J Clin Oncol. 1995. PMID: 7602366 Clinical Trial.

3

The use of the Calvert formula to determine the optimal carboplatin dosage.

van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. van Warmerdam LJ, et al. J Cancer Res Clin Oncol. 1995;121(8):478-86. doi: 10.1007/BF01218365. J Cancer Res Clin Oncol. 1995. PMID: 7642691

4

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.

van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, de Boer-Dennert M, Maes RA, Beijnen JH. van Warmerdam LJ, et al. Cancer Chemother Pharmacol. 1995;35(3):237-45. doi: 10.1007/BF00686554. Cancer Chemother Pharmacol. 1995. PMID: 7805183 Free article. Clinical Trial.

5

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

van Warmerdam LJ, Rodenhuis S, van Tellingen O, Maes RA, Beijnen JH. van Warmerdam LJ, et al. Among authors: van tellingen o. Cancer Chemother Pharmacol. 1994;35(2):179-81. doi: 10.1007/BF00686644. Cancer Chemother Pharmacol. 1994. PMID: 7987998 Clinical Trial.

6

Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and response.

ten Bokkel Huinink WW, van Warmerdam LJ, Dubbelman AC, McVie JG, Beijnen JH. ten Bokkel Huinink WW, et al. Among authors: van warmerdam lj. Ann Oncol. 1994 Feb;5(2):133-9. doi: 10.1093/oxfordjournals.annonc.a058764. Ann Oncol. 1994. PMID: 8186156 Free article. Clinical Trial.

7

Limited-sampling models for anticancer agents.

van Warmerdam LJ, ten Bokkel Huinink WW, Maes RA, Beijnen JH. van Warmerdam LJ, et al. J Cancer Res Clin Oncol. 1994;120(7):427-33. doi: 10.1007/BF01240143. J Cancer Res Clin Oncol. 1994. PMID: 8188737 Review.

8

Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. van Warmerdam LJ, et al. Cancer Chemother Pharmacol. 1996;37(3):266-70. doi: 10.1007/BF00688327. Cancer Chemother Pharmacol. 1996. PMID: 8529288

9

Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?

van Warmerdam LJ, van Tellingen O, ten Bokkel Huinink WW, Rodenhuis S, Maes RA, Bijnen JH. van Warmerdam LJ, et al. Among authors: van tellingen o. Ther Drug Monit. 1995 Oct;17(5):465-70. doi: 10.1097/00007691-199510000-00006. Ther Drug Monit. 1995. PMID: 8585109 Clinical Trial.

10

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.

van Warmerdam LJ, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JH, ten Bokkel Huinink WW, Davies BE, Maes RA, Verweij J, Beijnen JH. van Warmerdam LJ, et al. Cancer Chemother Pharmacol. 1996;38(3):254-60. doi: 10.1007/s002800050479. Cancer Chemother Pharmacol. 1996. PMID: 8646800 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters